Mira Pharmaceuticals appoints Dr. Itzchak Angel as Chief Scientific Advisor

Mira Pharmaceuticals announces the appointment of pharmaceutical executive Dr. Itzchak Angel as its new Chief Scientific Advisor. “Notably, at Synthelabo, later acquired by Sanofi-Aventis, Dr. Angel played a pivotal role in advancing several drugs, including Litoxetine for depression and Deriglidole for Type-II diabetes, from conception to Investigational New Drug applications and clinical trials. Additionally, his activities contributed to the development and marketing of Mizollen, Xatral and Ambien,” Mira stated. Dr. Angel stated, “I am thrilled to contribute to MIRA’s pioneering efforts in addressing the challenges in neurologic and neuropsychiatric disorders. I look forward to applying my experience and insights to help advance MIRA.”